PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33046366-0	2021	The prognostic value of serum MMP-7 levels in prostate cancer patients who received docetaxel, abiraterone, or enzalutamide therapy.	Docetaxel	84-93	matrix metallopeptidase 7	Homo sapiens	30-35	
33046366-12	2021	CONCLUSIONS: We confirmed the prognostic value of pretreatment MMP-7 serum level and its changes as independent predictors of survival in DOC-treated mCRPC patients.	Docetaxel	138-141	matrix metallopeptidase 7	Homo sapiens	63-68	
33046366-2	2021	We recently identified MMP-7 as a potential serum marker for the prediction of response and survival in mCRPC patients who received docetaxel (DOC) chemotherapy.	Docetaxel	132-141	matrix metallopeptidase 7	Homo sapiens	23-28	
33046366-2	2021	We recently identified MMP-7 as a potential serum marker for the prediction of response and survival in mCRPC patients who received docetaxel (DOC) chemotherapy.	Docetaxel	143-146	matrix metallopeptidase 7	Homo sapiens	23-28	
29802777-0	2018	Matrix metalloproteinase 7, soluble Fas and Fas ligand serum levels for predicting docetaxel resistance and survival in castration-resistant prostate cancer.	Docetaxel	83-92	matrix metallopeptidase 7	Homo sapiens	0-26	
29802777-4	2018	RESULTS: Higher pretreatment serum MMP-7, sFas and prostate-specific antigen (PSA) levels were significantly associated with both docetaxel resistance (P = 0.007, P = 0.001, P < 0.001, respectively) and shorter cancer-specific survival (P < 0.001, P = 0.041, P < 0.001, respectively).	Docetaxel	130-139	matrix metallopeptidase 7	Homo sapiens	35-40	
29802777-5	2018	High MMP-7 level remained an independent predictor of both docetaxel resistance (hazard ratio [HR] 2.298, 95% confidence interval [CI]: 1.354-3.899; P = 0.002) and poor cancer-specific survival (HR 2.11, 95% CI: 1.36-3.30; P = 0.001) in multivariable analyses.	Docetaxel	59-68	matrix metallopeptidase 7	Homo sapiens	5-10	
29802777-7	2018	CONCLUSIONS: Pretreatment serum MMP-7 levels may help to select patients with CRPC who are likely to benefit from docetaxel chemotherapy.	Docetaxel	114-123	matrix metallopeptidase 7	Homo sapiens	32-37	
32203786-0	2020	Novel octapeptide-DTX prodrugs targeting MMP-7 as effective agents for the treatment of colorectal cancer with lower systemic toxicity.	Docetaxel	18-21	matrix metallopeptidase 7	Homo sapiens	41-46	
32203786-10	2020	Thus, 9a, an MMP-7 polypeptide prodrug of DTX, has been identified as a promising candidate for the treatment of CRC.	Docetaxel	42-45	matrix metallopeptidase 7	Homo sapiens	13-18